Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche CellCept labeling discussions continue following Feb. 11 approval of heart transplant indication.

Executive Summary

ROCHE CELLCEPT LABELING NEGOTIATIONS CONTINUE AFTER APPROVAL FOR HEART TRANSPLANT indication. CellCept (mycophenolate mofetil) was approved Feb. 11 for use in combination with cyclosporine and corticosteroids for the prevention of organ rejection following cardiac transplants. Roche said it would begin promoting CellCept for the new indication once labeling negotiations have been completed and after FDA has cleared its promotional materials. The company said CellCept's price would not change; the cost for a 3 g daily dose for the cardiac indication would be $19.14.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel